

AMENDMENTS TO THE CLAIMS:

Please cancel claims 21 - 28. None of the other claims are amended.

LISTING OF THE CLAIMS

1 – 28. (Cancelled).

29. (Previously Presented) A method of treating inflammatory bowel disease, comprising:

administering a therapeutically effective amount of a therapeutic composition comprising 1α -hydroxyvitamin D₂ to a subject suffering from the symptoms of inflammatory bowel disease, wherein said inflammatory bowel disease is selected from the group consisting of ulcerative colitis and Crohn's disease.

30. (Previously Presented) The method of Claim 29, wherein said therapeutically effective amount comprises a daily dose of between 0.1 μ g and 20 μ g per 160 pounds of said subject.

31. (Previously Presented) The method of Claim 29, wherein said therapeutically effective amount comprises a daily dose of between 0.5 μ g and 10 μ g per 160 pounds of said subject.

32. (Previously Presented) The method of Claim 29, wherein said therapeutically effective amount comprises a daily dose of between 3.0 μ g and 10 μ g per 160 pounds of said subject.

33. (Previously Presented) The method of Claim 29, wherein said administering is conducted in a continuous manner.

34. (Previously Presented) The method of Claim 29, wherein said administering is via a transdermal patch.

35. (Previously Presented) The method of Claim 29, wherein said administering is via a suppository.

36. (Previously Presented) The method of Claim 29, wherein said administering is via a slow release oral formulation.

37. (Previously Presented) A method of treating inflammatory bowel disease, comprising:

administering a therapeutically effective amount of a therapeutic composition comprising 19-nor-1,25-dihydroxyvitamin D₂ to a subject suffering from the symptoms of inflammatory bowel disease, wherein said inflammatory bowel disease is selected from the group consisting of ulcerative colitis and Crohn's disease.

38. (Previously Presented) The method of Claim 37, wherein said therapeutically effective amount comprises a daily dose of between 0.1 µg and 20 µg per 160 pounds of said subject.

39. (Previously Presented) The method of Claim 37, wherein said therapeutically effective amount comprises a daily dose of between 0.5 µg and 10 µg per 160 pounds of said subject.

40. (Previously Presented) The method of Claim 37, wherein said therapeutically effective amount comprises a daily dose of between 3.0 µg and 10 µg per 160 pounds of said subject.

41. (Previously Presented) The method of Claim 37, wherein said administering is conducted in a continuous manner.

42. (Previously Presented) The method of Claim 37, wherein said administering is via a transdermal patch.

43. (Previously Presented) The method of Claim 37, wherein said administering is via a suppository.

44. (Previously Presented) The method of Claim 37, wherein said administering is via a slow release oral formulation.